CA3008607A1 — A medicament for treating influenza characterized by combining a cap-dependent endonuclease inhibitor and an anti-influenza drug

USPTO Abstract

A) Formula (I) A medicine that is useful for treating or preventing influenza, etc., said medicine being characterized by comprising a combination of: (A) a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the same [in formula (I): P represents a hydrogen atom or a prodrug-forming group; A1 represents CR1AR1B, S or O; A2 represents CR2AR2B, S or O; A3 represents CR3AR3B, S or O; A4's independently represent CR4AR4B, S or O; (wherein: the ring-constituting atoms of the ring formed by A1, A2, A3, A4's, the nitrogen atom adjacent to A1 and the carbon atom adjacent to A4's include 1 or 2 hetero atoms; R1A and R1B independently represent a hydrogen atom, halogen, alky, etc.; R2A and R2B independently represent a hydrogen atom, halogen, alky, etc.; R3A and R3B independently represent a hydrogen atom, halogen, alky, etc.; R4A's independently represent a hydrogen atom, halogen, alky, etc.; R4B's independently represent a hydrogen atom, halogen, alky, etc.; and R3A and R3B may form, together with the carbon atom adjacent thereto, a non-aromatic carbon ring or a non-aromatic heterocyclic ring); n is an integer of 1-2; and R1 is a group represented by formula (2), etc.]; with (B) a compound having an anti-influenza effect, a pharmaceutically acceptable salt thereof, or a solvate of the same, and/or an antibody having an anti-influenza effect.